Furthermore, combinations such as the EGFR-targeting drug erlotinib with bevacizumab, and cetuximab with cisplatin, have demonstrated substantial benefits in extending the survival time of breast cancer patients (Symonds et al., 2019) and alleviating symptoms (Baselga et al., 2013), respectively. This evidence concerns the gene EGFR and breast carcinoma.